Bayer/Onyx's Nexavar succeeds in first Phase II breast cancer trial
This article was originally published in Scrip
Executive Summary
Bayer/Onyx Pharmaceutical's oral multi-targeted kidney and liver cancer drug Nexavar (sorafenib) has met its primary progression-free survival (PFS) endpoint in its first randomised Phase II trial in advanced breast cancer.